Why Teva Pharmaceutical Industries (NYSE:TEVA) is on investors’ radar today

Teva Pharmaceutical Industries (NYSE:TEVA) has drawn fresh attention after recent share price moves, with the stock showing mixed short term returns but a stronger gain over the past 3 months.

While the latest 1 day share price return of 0.63% and 7 day return of 2.96% show some cooling at a recent price of US$34.47, the 90 day share price return of 37.17% and very strong 1 year total shareholder return of 105.06% indicate that momentum has been building over a longer stretch as investors reassess growth prospects and risk around Teva’s turnaround story.

If Teva’s move has caught your eye and you want to see what else is setting up for potential growth, take a moment to scan our 26 healthcare AI stocks as another source of ideas.

With Teva trading at US$34.47, a discount to both one estimate of intrinsic value and the average analyst price target, the key question is whether this reflects lingering risk or whether the market is already pricing in future growth.

Most Popular Narrative: 6.3% Undervalued

Teva’s most followed narrative places fair value at about $36.77, a touch above the recent $34.47 price. This puts the focus squarely on what is driving that gap.

The accelerating launch cadence of biosimilars (with 8 launches targeted through 2027 and a goal to double biosimilar revenue), backed by favorable regulatory trends increasing biosimilar adoption in major markets, should unlock incremental, higher-margin revenue streams and offset headwinds from traditional generics, powering long-term EBITDA growth.

Curious how a modest revenue growth profile can still back a higher valuation? The narrative leans on a different profit mix, richer margins, and a future earnings multiple that may surprise you.

Result: Fair Value of $36.77 (UNDERVALUED)

However, this depends on Teva keeping its heavy debt in check and delivering on a pipeline where delays or weaker uptake could quickly challenge that 6.3% undervalued case.

Another View: Market Multiple Sends a Different Signal

The fair value narrative suggests Teva looks about 6.3% undervalued at US$34.47, but the share price is telling a different story when you look at earnings. At a P/E of 28.1x, Teva trades above the US Pharmaceuticals industry at 21.2x, its peer average at 20.8x, and even above its own fair ratio of 25.6x. This points to a market that is already paying up for future progress. So is this a sensible premium, or a sign that expectations are running ahead of delivery?

Build Your Own Teva Pharmaceutical Industries Narrative

If you see the story differently or prefer to weigh the numbers yourself, you can shape a full Teva thesis in just minutes: Do it your way.

A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Ready for more investment ideas?

If Teva has sharpened your focus, do not stop here; use this momentum to scan a wider field of opportunities that could suit your goals.

• Target potential mispricings by checking companies our screener flags as 52 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them.
• Strengthen your income focus by reviewing 14 dividend fortresses that aim to combine higher yields with resilient business models.
• Prioritise resilience by scanning 82 resilient stocks with low risk scores for companies that our model scores with lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.